Market Runner: Could Vascular Solutions, Inc. See a Reversal After Breaking Its 52-Week High?

Market Runner: Could Vascular Solutions, Inc. See a Reversal After Breaking Its 52 Week High?

The stock of Vascular Solutions, Inc. (NASDAQ:VASC) hit a new 52-week high and has $69.34 target or 29.00% above today’s $53.75 share price. The 6 months bullish chart indicates low risk for the $963.89M company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $69.34 price target is reached, the company will be worth $279.53 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 46,094 shares traded hands. Vascular Solutions, Inc. (NASDAQ:VASC) has risen 41.15% since April 19, 2016 and is uptrending. It has outperformed by 37.29% the S&P500.

Vascular Solutions, Inc. (NASDAQ:VASC) Ratings Coverage

Out of 3 analysts covering Vascular Solutions (NASDAQ:VASC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Solutions has been the topic of 3 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Vascular Solutions, Inc. (NASDAQ:VASC) earned “Overweight” rating by Piper Jaffray on Tuesday, August 11. Needham initiated Vascular Solutions, Inc. (NASDAQ:VASC) on Thursday, October 6 with “Buy” rating.

According to Zacks Investment Research, “Vascular Solutions Inc. manufactures, markets and sells the Vascular Solutions Duett sealing device, which enables cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting. Its product combines a simple balloon catheter delivery mechanism with a powerful, proprietary procoagulant. The company believes its product offers advantages over both manual compression and the three other FDA-approved devices used to seal the puncture site following the catheterization.”

Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.01, from 1.19 in 2016Q1. The ratio improved, as 10 funds sold all Vascular Solutions, Inc. shares owned while 44 reduced positions. 15 funds bought stakes while 49 increased positions. They now own 14.00 million shares or 4.98% more from 13.33 million shares in 2016Q1.
National Bank Of Montreal Can accumulated 4,848 shares or 0% of the stock. State Board Of Administration Of Florida Retirement Sys holds 0% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 10,664 shares. Granahan Invest Ma owns 162,646 shares or 0.25% of their US portfolio. Credit Suisse Ag, a Switzerland-based fund reported 18,561 shares. Renaissance Tech Ltd Liability Corp holds 0.04% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 442,700 shares. Moreover, Comerica Bancorporation has 0.01% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 17,344 shares. The Tennessee-based First Mercantile Com has invested 0.01% in Vascular Solutions, Inc. (NASDAQ:VASC). Allianz Asset Ag accumulated 208,043 shares or 0% of the stock. Federated Investors Pa has invested 0% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC). Teachers Retirement Systems Of The State Of Kentucky holds 0.02% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 35,575 shares. The Minnesota-based Ameriprise Financial has invested 0.01% in Vascular Solutions, Inc. (NASDAQ:VASC). Citigroup Inc last reported 0% of its portfolio in the stock. Argent Capital Mngmt Limited Company has invested 0.2% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC). Envestnet Asset Mgmt Incorporated, a Illinois-based fund reported 5,859 shares. Strs Ohio holds 0% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 15,500 shares.

Insider Transactions: Since May 24, 2016, the stock had 0 insider buys, and 2 insider sales for $2.27 million net activity. ROOT HOWARD had sold 34,418 shares worth $1.34 million. On Wednesday, July 27 RUTSTEIN WILLIAM sold $463,109 worth of the stock or 10,011 shares.

Another recent and important Vascular Solutions, Inc. (NASDAQ:VASC) news was published by Startribune.com which published an article titled: “Vascular Solutions, CEO acquitted of federal charges in off-label case” on February 26, 2016.

VASC Company Profile

Vascular Solutions, Inc., incorporated on December 20, 1996, is a medical device firm focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. The Company’s products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Firm creates minimally invasive medical devices and then delivers these products and related services to physicians through its direct domestic sales force and its international distribution network.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment